Previous 10 | Next 10 |
BofA Securities screened for stocks with the the characteristics most likely to attract suitors, both in the large- and small-cap universes. For S&P 500 (SP500) (SPY) targets, BofA: Screens based on its preferred valuation metric of free cash flow to enterprise value (FCF/EV) for those tr...
Catalyst Pharmaceuticals (NASDAQ:CPRX) Q1 non-GAAP EPS grew +63.64% Y/Y to $0.18 and the company reaffirmed its FY22 revenue outlook. Total revenues rose +42.66% to $43.03M Y/Y. The company said the increase reflected steady growth for its drug Firdapse, to treat pediatric patients with ...
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Ali Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeff Del Carmen - Chief Commercial Officer Steven Mille...
Catalyst has outperformed during 2022 despite a brutal biotech market. Catalyst minds its knitting and does well by doing so. Catalyst reported strong earnings for Q1 2022. For further details see: Catalyst: Upside Outlier - In Search Of A Catalyst
Catalyst Pharmaceuticals press release (NASDAQ:CPRX): Q1 Non-GAAP EPS of $0.18. Revenue of $43.09M (+42.6% Y/Y). Shares +1.6%. Guidance: The Company continues to forecast full year 2022 total revenues to be in the range of between $195 million and $205 million, representing a 38% - 45% i...
Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE ® Significant Cash Position of $198 Million and No Funded Debt Advanced Plans to Diversify and Invest in In...
CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcos Dorados ( ARCO ): A fast food franchisee serving Latin America. Catalyst Pharmaceuticals ( CPRX ): This biopharmaceutical firm focuses on rare debilitating neuromuscular and neurodegenerative diseases. ...
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) traded today at a new 52-week high of $8.41. So far today approximately 301,000 shares have been exchanged, as compared to an average 30-day volume of 1.3 million shares. Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) defies analysts with a curren...
Start Time: 08:30 End Time: 09:31 Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2021 Earnings Conference Call March 17, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Alicia Grande - VP, CFO and Treasurer Steven Miller - COO and Chief Scientific Of...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
2024-05-15 08:00:00 ET Despite some turbulence, growth stocks have been on a bull run since the 2008 financial crisis. Groundbreaking innovations in technology and healthcare have been the primary drivers behind this trend. Which growth stocks stand out as top buys right now? Healthcare...
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE&...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...